Cilomilast

N. catalogoS1455 Lotto:S145501

Stampa

Dati tecnici

Formula

C20H25NO4

Peso molecolare 343.42 Numero CAS 153259-65-5
Solubilità (25°C)* In vitro DMSO 69 mg/mL (200.92 mM)
Ethanol 50 mg/mL (145.59 mM)
Water Insoluble
In vivo (Aggiungere i solventi al prodotto singolarmente e in ordine.)
Homogeneous suspension
CMC-NA
≥5mg/ml Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
* <1 mg/ml significa leggermente solubile o insolubile.
* Si prega di notare che Selleck testa la solubilità di tutti i composti internamente e la solubilità effettiva può differire leggermente dai valori pubblicati. Ciò è normale ed è dovuto a leggere variazioni da lotto a lotto.
* Spedizione a temperatura ambiente (I test di stabilità mostrano che questo prodotto può essere spedito senza alcuna misura di raffreddamento.)

Preparazione delle soluzioni stock

Attività biologica

Descrizione Cilomilast (SB-207499) è un potente inibitore della PDE4 con IC50 di circa 110 nM, ha attività antinfiammatoria e bassa attività sul sistema nervoso centrale. Fase 3.
Target
LPDE4
(Cell-free assay)
HPDE4
(Cell-free assay)
100 nM 120 nM
In vitro Cilomilast produces a concentration-dependent increase in cAMP content in U937 cells. This compound produces a concentration-dependent increase in cAMP content in U937 cells. In isolated human monocytes, it and (R)-rolipram are equipotent at suppressing LPS-induced TNF-α formation with -log (IC50) of 7.0 and 7.2, respectively. Both this compound and (R)-rolipram produces a modest prevention of fMLP-induced degranulation of human neutrophils. It and (R)-rolipram are equipotent at suppressing neutrophil activation with -log (IC50) of 7.1 and 6.4, respectively. This chemical significantly decreases the expression of TNF-α in the cornea and IL-1α, IL-1β, and TNF-α in the conjunctivaas compared to vehicle control. Its treatment markedly decreases the presence of CD11b+ antigen-presenting cells in the central and peripheral cornea, and leads to decreased conjunctival expression of cytokines IL-6, IL-23, and IL-17. Moreover, it decreases the expression of IL-17 and IL-23 in the draining lymph nodes. It reduces TLR4 expression, IL-8 release and neutrophil chemotactic activity as well as it increased IP-10 release and lymphocyte chemotactic activity.
In vivo Cilomilast inhibits human TNFα production with oral ED50 of 4.9 mg/kg. In contrast to their equipotent activity against TNFα production, this compound (ED50 = 2.3 mg/kg, p.o.) is 10-fold less potent than R-rolipram (ED50 = 0.23 mg/kg, p.o.) in reversing reserpine-induced hypothermia, a model of antidepressant activity. In time course studies, this chemical (30 mg/kg, p.o.) suppresses TNFα production for at least 10 hour. The ability of this compound to modulate interleukin-4 productionin vivo is assessed in a chronic oxazolone-induced contact sensitivity model in Balb/c mice. Topical administration of this chemical (1000 μg) inhibits intralesional concentrations of interleukin-4. Orally administered cilomilast dose-dependently inhibits production of interleukin-4, TNF-α, and cysteinyl leukotrienes, as well as leukocyte infiltration in bronchoalveolar lavage fluid from the airways of ovalbumin-sensitized Brown Norway rats .
Caratteristiche Cilomilast è stato utilizzato per trattare la broncopneumopatia cronica ostruttiva (BPCO) per molti anni.

Protocollo (da riferimento)

Saggio cellulare:[2]
  • Linee cellulari

    U937 cells

  • Concentrazioni

    0.1-10 μM

  • Tempo di incubazione

    5 min

  • Metodo

    U937 cells (1-2 × 10 6) are incubated at 37 °C in a shaking water bath with Cilomilast for 1 min before the addition of 0.1 μM PGE2 (total volume of 200 μL). The incubation proceeds for an additional 4 min and is stopped by the addition of 0.1 mL of HClO4 (17.5%), neutralized with 0.15 ml of K2CO3 (1.0 M) and diluted to 1 mL with sodium acetate buffer. Samples are centrifuged at 3000 × g for 10 min. Aliquots of the supernatant fraction are assayed for cAMP content by radioimmunoassay using commercially available kits.

Studio sugli animali:[1]
  • Modelli animali

    Balb/c, CD-1 and C57B1/6 male mice weighing from 18 to 25 g with human monocytes or endotoxin-induced shock

  • Dosaggi

    3, 6, 12, 25, 50 mg/kg

  • Somministrazione

    Gavage

Riferimenti

  • https://pubmed.ncbi.nlm.nih.gov/9808700/
  • https://pubmed.ncbi.nlm.nih.gov/9435206/
  • https://pubmed.ncbi.nlm.nih.gov/22577075/
  • https://pubmed.ncbi.nlm.nih.gov/21382614/
  • https://pubmed.ncbi.nlm.nih.gov/21315169/

Convalida del prodotto da parte del cliente

LNCaP-C4 prostate cancer cells were suspended in matrigel and transplanted under the kidney capsule of male nude mice hosts. Mice were treated with vehicle-only (10% EtOH, 90% olive oil) control, cilomilast or NVP-ABE171 by gavage (n=7-11 for each respective group)The xenografts LNCaP-C4 xenografts were excised, fixed in formalin, and embedded in paraffin blocks.  IHC with Ki67 (proliferation), TUNEL (apoptosis), or p21 (senescence) was performed. Representative Ki67 and TUNEL photomicrographs for cilomilast and NVP-ABE171 treatment group are shown.

Dati da [ Mol Cancer Res , 2014 , 10.1158/1541-7786.MCR-14-0110 ]

<p> </p><div>ALP activity levels relative to control: (a) samples treated with 300 ng/mL of BMP-2; (b) samples treated with 30 ng/mL of BMP-2. Cells cultured with 1% DMSO for 11 days were used as control cells. Bar represent mean  SD for 8 experiments. PDE4 I =PDE4 inhibitor, SM =standard medium, OM =osteogenic medium.</div>

Dati da [ Biochimie , 2012 , 94, 2360e2365 ]

<p> </p><div>ALP activity levels relative to samples treated with DMSO. Cells cultured with</div><div>1% DMSO for 11 days were used as control cells. The inset shows a schematic representation of the PDE4 inhibitor (PDE4 I) and H89 pathways. PDE4 I blocks the</div><div>degradation of the intracellular cAMP signalling by PDE, and increases the PKA levels. By the use of an efficient PKA inhibitor, H89, the pathway activated downstream by PKA is completely blocked. Bar represent mean  SD for 8 experiments.</div>

Dati da [ Biochimie , 2012 , 94, 2360e2365 ]

Phosphodiesterase (PDE) 4 inhibitors increase formoterol-induced cAMP and MKP-1 mRNA expression. Growth-arrested ASM cells were pretreated for 30 minutes with the PDE4 inhibitors cilomilast (A and B, 0.1-10 μM). The impact of PDE4 inhibition was assessed by: (A) measuring cAMP production in response to stimulation with 10 nM formoterol for 15 minutes in comparison to vehicle (results expressed as percentage of formoterol-induced cAMP); and (B) measuring MKP-1 mRNA expression by RT-PCR in response to stimulation with 10 nM formoterol for 1 hour in comparison to vehicle (results expressed as percentage of formoterol-induced MKP-1). Statistical analysis was performed using one-way ANOVA then Fisher’s post hoc multiple comparison test. *Significant increase (P < 0.05). Data are mean ± SEM values from n = 7 primary ASM cell cultures.

Dati da [ , , Am J Respir Cell Mol Biol, 2015, 52(5):634-40 ]

Selleck's Cilomilast È stato citato da 18 Pubblicazioni

Inhibitors of Phosphodiesterase 4, but Not Phosphodiesterase 3, Increase β2-Agonist-Induced Expression of Antiinflammatory Mitogen-Activated Protein Kinase Phosphatase 1 in Airway Smooth Muscle Cells [ American Journal of Respiratory Cell and Molecular Biology, May 2015, 634-640] PubMed: 25296132
Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury [ American Journal of Physiology-Renal Physiology, March 1, 2020, F576-F588] PubMed: 31961716
Phosphodiesterase 4D Inhibitors Limit Prostate Cancer Growth Potential [ Molecular Cancer Research, January 2015, 149-160] PubMed: 25149359
DMAP1 Deficiency Suppresses Lung Cancer Progression by Destabilizing Replication Fork and Activating IFN Signaling-Mediated Anti-tumor Immunity [ Advanced Science, 2026, nan] PubMed: 41904944
Aberrant TCF21 upregulation in adenomyosis impairs endometrial decidualization by increasing PDE4C expression [ Biochim Biophys Acta Mol Basis Dis, 2025, 1871(1):167526] PubMed: 39326465
Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury. [ Am J Physiol Renal Physiol, 2020, 318(3):F576-F588] PubMed: 31961716
Inhibition of PDE4/PDE4B improves renal function and ameliorates inflammation in cisplatin-induced acute kidney injury [ American Journal of Physiology-Renal Physiology, 2020, F576-F588] PubMed: 31961716
A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes [ Journal of Pharmaceutical and Biomedical Analysis, 2016, 47-60] PubMed: nan
A multi-targeted liquid chromatography-mass spectrometry screening procedure for the detection in human urine of drugs non-prohibited in sport commonly used by the athletes [ Journal of Pharmaceutical and Biomedical Analysis, 2016, 47-60]
A multi-targeted liquid chromatography–mass spectrometryscreening procedure for the detection in human urine of drugsnon-prohibited in sport commonly used by the athletes [Mazzarino M, et al. J Pharm Biomed Anal, 2016, 117:47-60] PubMed: 26342446

POLITICA DI RESO
La politica di reso incondizionato di Selleck Chemical garantisce ai nostri clienti un'esperienza di acquisto online senza problemi. Se non sei in alcun modo soddisfatto del tuo acquisto, puoi restituire qualsiasi articolo entro 7 giorni dalla ricezione. In caso di problemi di qualità del prodotto, sia relativi al protocollo che al prodotto, puoi restituire qualsiasi articolo entro 365 giorni dalla data di acquisto originale. Si prega di seguire le istruzioni seguenti per la restituzione dei prodotti.

SPEDIZIONE E CONSERVAZIONE
I prodotti Selleck vengono trasportati a temperatura ambiente. Se ricevi il prodotto a temperatura ambiente, ti assicuriamo che il Dipartimento di Ispezione Qualità di Selleck ha condotto esperimenti per verificare che la conservazione a temperatura normale per un mese non influirà sull'attività biologica dei prodotti in polvere. Dopo la raccolta, conservare il prodotto secondo le indicazioni descritte nella scheda tecnica. La maggior parte dei prodotti Selleck è stabile nelle condizioni raccomandate.

NON PER USO UMANO, DIAGNOSTICO VETERINARIO O TERAPEUTICO.